Advertisement
U.S. markets open in 8 hours 13 minutes
  • S&P Futures

    5,207.75
    -7.00 (-0.13%)
     
  • Dow Futures

    39,207.00
    -16.00 (-0.04%)
     
  • Nasdaq Futures

    18,175.75
    -55.75 (-0.31%)
     
  • Russell 2000 Futures

    2,047.20
    -2.60 (-0.13%)
     
  • Crude Oil

    82.56
    -0.16 (-0.19%)
     
  • Gold

    2,162.10
    -2.20 (-0.10%)
     
  • Silver

    25.30
    +0.03 (+0.12%)
     
  • EUR/USD

    1.0871
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2717
    -0.0012 (-0.09%)
     
  • USD/JPY

    150.1910
    +1.0930 (+0.73%)
     
  • Bitcoin USD

    65,117.64
    -3,250.53 (-4.75%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,880.60
    +140.20 (+0.35%)
     

FDA approves Botox Cosmetic to improve the appearance of crow’s feet

The U.S. Food and Drug Administration approved a new use for Botox Cosmetic for the temporary improvement in the appearance of moderate to severe lateral canthal lines, known as crow’s feet, in adults. Botox Cosmetic is the only FDA approved drug treatment option for lateral canthal lines. The FDA approved Botox Cosmetic in 2002 for the temporary improvement of glabellar lines, known as frown lines, in adults. OnabotulinumtoxinA is marketed as Botox and Botox Cosmetic. Botox Cosmetic is manufactured by Allergan.

Advertisement